≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Other and unspecified primary disorders of muscles

DOID EFO Endpoint Browser PheWeb

G6_MUSCOTHUNS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

264

4. Check minimum number of events

None

264

5. Include endpoints

None

264

6. Filter based on genotype QC (FinnGen only)

264

Control definitions (FinnGen only)

Control exclude
G6_MYONEU

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1716 804 901
Only index persons 1507 719 788
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.03
Only index persons 0.03 0.03 0.03
Median age at first event (years)
Whole population 51.52 52.43 50.70
Only index persons 51.61 52.14 51.12

-FinnGen-

Key figures

All Female Male
Number of individuals 264 137 127
Unadjusted period prevalence (%) 0.05 0.05 0.06
Median age at first event (years) 51.61 51.78 51.44

-FinRegistry-

Age distribution of first events

0102030405060708090050100150200250300AgeIndividuals

-FinnGen-

Age distribution of first events

01020304050607080900510152025303540455055AgeIndividuals

-FinRegistry-

Year distribution of first events

197019751980198519901995200020052010201520202022050100150200250300350400YearIndividuals

-FinnGen-

Year distribution of first events

19701975198019851990199520002005201020152020202301020304050607080YearIndividuals

-FinRegistry-

Cumulative Incidence Function

01020304050607080901000.00.10.20.30.40.50.60.70.80.91.0AgeProbability of first incidence (%)

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
242
Matched controls
2421
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
+∞
210.3
170
*
G71.8
ICD-10 Finland
Other primary disorders of muscles
+∞
103.8
92
*
G72.9
ICD-10 Finland
Myopathy, unspecified
593.0
84.6
79
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
64.5
59
*
G71.18
ICD-10 Finland
Other myotonic disease
+∞
34.2
32
*
R1250
NOMESCO Finland
Evaluation of functional capability
30.6
30.9
41
16
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
118.0
29.4
31
*
NXL00
NOMESCO Finland
Biopsy of muscle
73.3
28.7
32
5
Z31.5
ICD-10 Finland
Genetic counselling
10.8
27.4
55
64
G72.8
ICD-10 Finland
Other specified myopathies
+∞
24.4
23
*
L28
ICPC
Limited function/disability (L)
5.1
19.8
70
179
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.4
19.3
54
104
G71.00
ICD-10 Finland
Muscular dystrophy benign [Becker]
+∞
19.0
18
*
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
+∞
19.0
18
*
N03AE01
ATC
clonazepam; systemic
7.4
17.4
43
69
M60.8
ICD-10 Finland
Other myositis
+∞
16.9
16
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.4
16.7
41
65
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
43.4
16.6
20
5
SPAT1229
SPAT
Assessment of need for aid
6.2
14.8
41
77
G71.0
ICD-10 Finland
Muscular dystrophy
+∞
14.7
14
*
G71.11
ICD-10 Finland
Dystrophia myotonica [Steinert]
+∞
14.7
14
*
J96.1
ICD-10 Finland
Chronic respiratory failure
17.2
14.2
22
14
N99
ICPC
Neurological disease other
32.2
14.1
18
6
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
79.8
13.7
15
*
G71.12
ICD-10 Finland
Myotonia congenita
+∞
13.7
13
*
M60.9
ICD-10 Finland
Myositis, unspecified
53.0
13.0
15
*
N18
ICPC
Paralysis/weakness
21.5
12.7
18
9
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.1
12.6
53
156
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
11.4
12.0
22
21
C10AX09
ATC
ezetimibe; oral
4.7
12.0
42
103
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
68.4
11.7
13
*
G71.06
ICD-10 Finland
Muscular dystrophy severe [Duchenne]
+∞
11.5
11
*
R4120
NOMESCO Finland
Occupational therapy
5.4
11.4
35
74
L99
ICPC
Musculoskeletal disease other
16.5
11.0
17
11
R13
ICD-10 Finland
Dysphagia
5.3
10.8
33
70
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
4.3
10.6
40
106
M33.2
ICD-10 Finland
Polymyositis
114.8
10.5
11
*
N28
ICPC
Limited function/disability (N)
17.0
10.5
16
10
G71.28
ICD-10 Finland
Other congenital myopathy
+∞
10.5
10
*
N03AX12
ATC
gabapentin; oral
3.5
10.1
50
168
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.2
9.9
58
219
R4110
NOMESCO Finland
Physiotherapy
2.7
9.9
86
416
N29
ICPC
Neurological sympt/complt other
14.2
9.8
16
12
XF404
NOMESCO Finland
Ambulatory ECG
4.2
9.8
38
103
N03AX16
ATC
pregabalin; oral
2.8
9.7
73
325
G71.25
ICD-10 Finland
Congenital muscular dystrophy NOS
+∞
9.4
9
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.6
9.3
81
389
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
14.4
9.3
15
11
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
4.0
8.8
35
97
N07AA02
ATC
pyridostigmine; systemic
51.9
8.7
10
*
N03AF01
ATC
carbamazepine; oral, rectal
6.1
8.7
23
41
L19
ICPC
Muscle symptom/complaint NOS
9.5
8.7
17
19
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
93.2
8.5
9
*
33030
ICD-8 Finland
Hereditary neuromuscular disorders, Progressive muscular dystrophy
+∞
8.4
8
*
M03BX01
ATC
baclofen; systemic
15.2
8.3
13
9
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.7
8.3
64
285
Z50.1
ICD-10 Finland
Other physical therapy
4.9
8.2
26
58
RF410
NOMESCO Finland
NA
34.6
8.1
10
*
A28
ICPC
Limited function/disability NOS
3.2
8.1
44
156
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.8
7.8
52
213
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
46.5
7.8
9
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.3
7.6
38
128
XA402
NOMESCO Finland
ENMG
8.1
7.5
16
21
QDA99
NOMESCO Finland
Other local destruction of skin of lower limb
82.5
7.5
8
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.3
7.5
38
130
3591A
ICD-9 Finland
Muscular dystrophies and other myopathies, Hereditary progressive muscular dystrophy
+∞
7.3
7
*
Z99.1
ICD-10 Finland
Dependence on respirator
+∞
7.3
7
*
M41.4
ICD-10 Finland
Neuromuscular scoliosis
+∞
7.3
7
*
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
7.3
7
*
R06.0
ICD-10 Finland
Dyspnoea
2.4
7.3
68
335
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
31.0
7.2
9
*
G47.3
ICD-10 Finland
Sleep apnoea
2.5
7.2
63
301
H02AB06
ATC
prednisolone; systemic
2.1
7.1
121
784
R52.2
ICD-10 Finland
Other chronic pain
5.1
7.0
21
44
RF420
NOMESCO Finland
NA
14.3
7.0
11
8
JDB10
NOMESCO Finland
Percutaneous gastrostomy
14.3
7.0
11
8
SPAT1231
SPAT
Assessment of adjustments needed in living environment
9.7
6.9
13
14
N06AX21
ATC
duloxetine; oral
3.3
6.8
33
109
RF120
NOMESCO Finland
NA
17.3
6.8
10
6
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.8
6.8
28
81
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
4.0
6.6
25
67
ZX120
NOMESCO Finland
Intravenous
3.1
6.3
35
125
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.3
6.3
18
36
TJD20
NOMESCO Finland
Change of gastrostomy tube
18.6
6.3
9
5
3599X
ICD-9 Finland
Muscular dystrophies and other myopathies, Myopathy, unspecified
+∞
6.3
6
*
SPAT1216
SPAT
Assessment of functional ability
2.7
6.0
41
169

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
14
39.58
73.07
1.5
1.6
7.40
8.33
u/l
0.11
40
14
175
588
6.86
52.92
4.3
2.1
1139.09
168.47
u/l
2.04
169
551
22
14
17.05
25.68
1.3
1.1
—
—
—
0
0
117
514
3.29
19.67
3.7
3.4
1281.64
1198.55
ng/l
0.05
110
438
171
1005
2.99
16.21
8.4
8.2
1.22
1.21
mmol/l
0.03
153
866
75
283
3.31
15.76
1.5
1.4
509.57
551.88
titre
0.09
23
64
159
929
2.79
14.72
8.8
7.3
1.21
1.22
mmol/l
0.37
152
853
56
215
3.04
11.13
6.8
5.9
2.26
1.92
mmol/l
0.35
48
176
142
867
2.38
10.82
5.8
5.4
36.21
36.10
g/l
0.09
137
814
56
219
2.98
10.75
6.8
5.8
6.17
5.79
kpa
2.18
56
213
42
140
3.38
10.52
3.3
3.5
138.89
186.36
ng/l
0.33
36
127
139
850
2.34
10.44
3.8
2.4
77.95
76.20
nmol/l
0.28
132
761
109
602
2.38
10.34
5.2
3.9
7.38
7.40
ph
0.74
18
105
50
199
2.87
9.23
11.5
9.2
—
—
—
0
0
212
1627
2.54
8.54
11.0
7.4
81.87
82.83
u/l
0.10
203
1526
110
652
2.18
8.45
3.7
3.0
43.74
45.25
e6/l
0.02
89
499
103
597
2.19
8.35
3.6
2.9
0.57
0.39
e6/l
0.27
82
441
97
549
2.21
8.34
3.6
2.9
—
—
—
0
0
47
191
2.78
8.31
5.5
5.6
4.62
4.67
kpa
0.07
47
186
151
1016
2.14
8.30
4.8
3.4
0.00
0.00
estimate
0.00
32
176
75
384
2.33
8.18
4.2
3.7
78.35
264.56
ng/l
1.57
65
285
10
11
9.41
8.13
3.7
3.6
87.60
151.75
ug/l
—
10
11
27
80
3.65
8.04
7.2
4.5
—
—
—
0
0
121
756
2.11
8.00
4.6
3.5
36.91
55.53
e6/l
0.51
94
532
149
1007
2.10
7.98
6.1
4.7
0.00
0.00
estimate
0.00
33
191
52
228
2.59
7.91
8.1
10.0
1.56
1.43
mmol/l
0.06
39
191
101
595
2.13
7.74
3.5
2.9
—
—
—
0
0
123
786
2.06
7.54
4.5
3.2
—
—
—
0
0
34
122
3.05
7.50
2.0
3.0
—
—
—
0
0
170
1229
2.08
7.34
7.6
5.4
6.11
6.62
mmol/l
4.76
162
1149
98
581
2.09
7.31
7.8
7.9
—
—
—
0
0
83
465
2.14
7.16
5.1
3.6
—
—
—
0
0
146
1010
2.00
7.00
4.9
3.4
0.00
0.00
estimate
0.00
31
187
109
683
2.01
6.91
3.3
3.5
2.38
2.36
mmol/l
1.20
100
602
25
78
3.44
6.89
1.3
1.3
0.20
1.63
u/ml
—
5
6
187
1418
2.09
6.86
4.8
4.1
—
—
—
0
0
156
1111
1.99
6.81
7.5
6.8
12.97
12.43
umol/l
0.14
148
1050
159
1143
1.98
6.72
10.2
7.4
0.18
0.20
e9/l
0.54
143
1010
35
136
2.81
6.69
4.7
7.8
—
—
—
0
0
155
1114
1.95
6.45
9.4
6.9
0.57
0.56
e9/l
0.05
139
963
155
1117
1.94
6.37
9.4
6.9
0.04
0.04
e9/l
0.15
139
970
155
1138
1.88
5.80
9.5
6.9
1.86
1.95
e9/l
0.54
138
1014
40
179
2.46
5.78
5.1
4.9
7.41
7.42
ph
—
9
13
62
335
2.11
5.74
2.8
2.8
2.45
1.99
e6/l
0.21
40
179
75
435
2.01
5.74
3.4
2.5
7.50
4.83
e6/l
0.69
70
387
64
352
2.08
5.65
3.3
2.7
2.47
2.44
mmol/l
1.13
58
301
28
107
2.81
5.52
4.0
5.1
9.69
8.99
kpa
1.12
28
102
170
1299
1.87
5.46
11.5
10.3
4.04
3.98
e9/l
0.15
154
1128
195
1562
1.95
5.36
6.0
4.2
11.46
10.62
mm/h
0.40
183
1431
110
740
1.83
5.32
2.2
1.8
87.89
98.37
pmol/l
1.86
54
366
20
65
3.25
5.18
2.8
2.3
—
—
—
0
0
48
244
2.18
5.16
3.1
1.6
—
—
—
0
0
38
175
2.37
5.15
1.9
1.4
—
—
—
0
0
73
446
1.88
4.70
2.1
2.2
2.46
1.20
mg/l
0.46
57
352
25
101
2.63
4.45
3.4
4.8
1.87
1.24
%
1.26
25
101
137
1020
1.71
4.44
14.0
9.6
0.00
0.00
e9/l
0.41
112
823
35
166
2.28
4.43
5.7
3.7
—
—
—
0
0
108
754
1.73
4.42
4.4
3.5
57.96
35.39
ng/l
0.76
88
500
82
530
1.79
4.37
9.2
4.3
—
—
—
0
0
20
73
2.88
4.29
1.7
2.2
2.22
4.26
ug/l
0.22
20
66
56
324
1.92
4.22
2.9
2.6
30.32
29.64
s
0.48
56
318
94
638
1.74
4.21
2.7
2.6
54.28
56.72
u/l
0.35
88
592
11
27
4.21
4.20
1.5
1.2
—
—
—
0
0
7
7
10.23
4.03
3.0
3.7
13.57
18.91
mmol/l
—
7
7
13
38
3.55
3.95
1.8
2.5
—
—
—
0
0
65
408
1.79
3.77
2.9
2.6
577.74
553.82
mosm/kgh2o
0.34
57
349
32
157
2.18
3.75
1.8
1.8
1.12
1.34
g/l
0.45
32
145
40
215
2.01
3.70
25.5
18.7
1.24
1.23
inr
—
8
24
13
40
3.37
3.67
1.0
1.1
—
—
—
0
0
76
503
1.72
3.66
2.8
2.3
3.04
3.16
mg/l
0.14
70
428
13
41
3.28
3.54
5.5
2.5
—
—
—
0
0
34
176
2.07
3.48
10.0
8.9
25.81
25.10
mmol/l
0.46
34
176
74
493
1.70
3.46
5.0
5.1
—
—
—
0
0
8
14
5.85
3.36
5.3
3.7
35.88
26.29
umol/l
—
8
14
192
1626
1.66
3.33
4.8
3.8
15.18
14.62
pmol/l
2.01
181
1476
78
533
1.66
3.29
6.1
3.7
0.00
0.02
estimate
0.68
32
186
29
145
2.12
3.25
1.2
1.4
323.02
355.58
u/ml
0.05
29
130
174
1444
1.60
3.22
4.4
3.6
—
—
—
0
0
218
1918
1.78
3.19
5.4
5.4
38.51
39.55
mmol/mol
0.82
206
1804
15
56
2.78
3.11
1.3
2.8
40.77
38.86
g/l
0.71
15
49
8
16
5.12
3.07
2.3
2.9
—
—
—
0
0
12
40
3.10
3.01
7.0
2.7
5.47
5.01
kpa
1.02
12
40
12
40
3.10
3.01
7.0
2.7
9.09
8.33
kpa
0.92
12
40
220
1951
1.77
3.00
5.8
4.5
1.93
1.88
mu/l
0.26
209
1788
133
1052
1.53
2.94
9.7
7.4
8.56
8.54
%
0.03
133
990
132
1045
1.53
2.89
9.6
7.1
2.68
2.96
%
0.96
132
977
28
145
2.04
2.88
5.9
5.2
—
—
—
0
0
53
338
1.71
2.87
2.0
1.6
1385.18
1224.93
nmol/l
0.40
42
256
13
47
2.86
2.86
1.0
1.1
—
—
—
0
0
129
1019
1.52
2.84
9.6
7.1
0.63
0.70
%
0.69
129
954
239
2186
1.99
2.77
21.5
13.0
19.70
22.27
mg/l
0.71
205
1675
13
48
2.80
2.76
2.0
2.1
—
—
—
0
0
8
19
4.31
2.70
3.9
1.6
28.04
16.40
umol/l
—
8
19
65
446
1.61
2.65
6.2
3.6
1.02
1.02
kg/l
—
9
52
25
129
2.04
2.60
1.6
1.2
—
—
—
0
0
28
152
1.94
2.54
1.3
1.6
—
—
—
0
0
11
39
2.90
2.50
1.2
2.2
—
—
—
0
0
7
16
4.46
2.49
1.3
2.1
—
—
—
0
0
79
578
1.52
2.42
3.7
2.8
—
—
—
0
0
28
155
1.90
2.41
1.6
1.2
100.59
176.66
iu/ml
—
8
63
48
314
1.65
2.36
2.4
2.2
—
—
—
0
0
71
512
1.53
2.32
2.6
3.1
335.67
6159.62
umol/l
1.98
61
442
25
135
1.94
2.31
6.2
5.4
24.60
24.50
mmol/l
0.06
25
130
8
23
3.55
2.29
1.0
1.1
—
—
—
0
0
70
505
1.53
2.28
1.6
1.5
2.14
2.27
g/l
0.30
43
295
113
898
1.45
2.28
3.6
2.8
124.04
109.04
ug/l
0.29
107
838
7
18
3.96
2.26
3.0
1.6
2.29
3.02
mg/l
—
7
18
211
1893
1.57
2.26
23.3
16.4
13.86
13.60
%
1.61
206
1863
9
29
3.18
2.24
1.7
2.2
—
—
—
0
0
43
277
1.66
2.24
1.3
1.2
—
—
—
0
0
5
9
5.64
2.22
1.6
1.0
—
—
—
0
0
5
9
5.64
2.22
1.6
1.0
—
—
—
0
0
5
9
5.64
2.22
1.6
1.0
—
—
—
0
0
7
19
3.75
2.16
1.3
2.4
—
—
—
0
0
6
14
4.36
2.16
1.0
1.2
—
—
—
0
0
40
257
1.66
2.11
1.5
1.7
—
—
—
0
0
104
823
1.44
2.11
2.3
2.0
—
—
—
0
0
8
25
3.27
2.11
2.0
1.3
—
—
—
0
0
7
20
3.57
2.07
1.3
2.3
24.21
18.00
ug/l
—
7
20
6
15
4.07
2.05
1.0
1.3
1.90
1.66
mmol/l
—
6
15
96
752
1.43
2.05
10.0
6.9
—
—
—
0
0
11
44
2.57
2.04
1.1
2.0
—
—
—
0
0
45
301
1.60
2.03
1.6
1.6
—
—
—
0
0
13
57
2.35
2.01
1.6
1.6
—
—
—
0
0
19
99
1.99
1.96
1.5
1.4
—
—
—
0
0
8
27
3.02
1.95
1.3
5.0
—
—
—
0
0
14
65
2.22
1.91
1.4
1.4
258.00
311.40
ug/g
—
9
36
14
65
2.22
1.91
1.5
1.6
—
—
—
0
0
17
86
2.04
1.89
3.2
5.6
0.23
0.23
g/l
—
10
43
61
444
1.49
1.89
1.8
1.5
23.09
22.22
nmol/l
0.15
53
369
27
161
1.75
1.87
4.0
5.1
0.00
0.02
%
—
5
46
6
17
3.59
1.85
3.7
15.1
13.05
12.08
%
—
6
17
81
628
1.42
1.80
3.3
3.3
7.00
7.92
mmol/l
1.00
76
536
10
41
2.50
1.77
1.5
5.6
—
—
—
0
0
7
24
2.97
1.73
1.7
4.4
—
—
—
0
0
5
13
3.90
1.72
1.4
1.2
—
—
—
0
0
21
119
1.83
1.72
4.3
3.4
4.75
4.65
pmol/l
0.21
21
106
81
633
1.40
1.71
3.4
2.5
—
—
—
0
0
8
31
2.63
1.67
1.6
1.1
—
—
—
0
0
6
19
3.21
1.67
1.5
1.1
—
—
—
0
0
6
19
3.21
1.67
2.8
3.3
93.33
338.89
e6/l
—
6
9
27
168
1.68
1.63
3.4
5.0
—
—
—
0
0
27
168
1.68
1.63
3.9
5.1
0.00
0.12
%
—
5
52
7
26
2.74
1.59
1.1
1.2
—
—
nmol/l
—
0
0
69
531
1.41
1.58
3.6
3.5
—
—
—
0
0
39
268
1.53
1.58
7.6
4.1
6.07
8.95
umol/l
0.97
29
239
5
15
3.38
1.53
1.0
1.3
—
—
—
0
0
20
117
1.77
1.50
1.2
1.6
13.11
25.43
iu/l
1.19
13
94
65
822
0.72
1.47
2.7
2.7
—
—
—
0
0
12
60
2.05
1.40
2.3
3.0
—
—
—
0
0
12
60
2.05
1.40
1.8
1.5
109.33
259.45
u/ml
—
6
31
7
29
2.45
1.40
2.9
3.0
322.29
591.77
e6/l
—
7
22
7
29
2.45
1.40
2.7
3.0
0.22
0.20
e9/l
—
7
22
19
112
1.75
1.39
2.7
2.4
—
—
—
0
0
9
41
2.24
1.38
3.6
8.1
—
—
—
0
0
26
168
1.61
1.38
4.0
4.9
4.80
0.33
%
—
5
42
94
778
1.32
1.35
10.1
7.4
1.27
1.20
inr
0.33
31
227
37
262
1.48
1.32
1.4
1.6
—
—
—
0
0
6
24
2.53
1.31
1.2
1.3
—
—
—
0
0
8
34
2.39
1.30
1.0
2.0
—
—
—
0
0
8
34
2.39
1.30
1.0
2.0
—
—
—
0
0
8
34
2.39
1.30
1.0
2.0
—
—
—
0
0
8
34
2.39
1.30
1.0
2.0
—
—
—
0
0
5
18
2.81
1.29
1.2
1.1
—
—
—
0
0
6
25
2.43
1.25
2.3
1.8
87.57
90.46
%
—
6
25
27
181
1.55
1.24
4.0
4.9
1.60
0.70
%
—
5
59
68
546
1.33
1.19
1.2
1.4
0.75
1.39
u/ml
0.93
12
146
20
126
1.64
1.18
2.8
2.3
—
—
—
0
0
5
20
2.53
1.15
2.4
3.7
—
—
—
0
0
7
30
2.37
1.13
2.4
2.6
—
—
—
0
0
43
325
1.39
1.10
1.2
1.2
3.39
6.97
u/ml
0.63
24
128
44
336
1.37
1.06
1.3
1.3
20.44
29.26
iu/ml
—
9
122
14
83
1.73
1.03
1.5
1.6
6.49
8.44
u/l
—
9
60
67
548
1.30
1.03
3.0
3.2
568.33
283.02
mg/l
0.21
52
358
27
192
1.45
0.97
1.7
4.4
31.58
28.73
ug/l
0.03
18
151
7
37
1.92
0.94
1.4
1.4
—
—
—
0
0
73
611
1.27
0.93
4.3
4.2
1.67
1.84
ug/l
0.29
68
546
6
29
2.09
0.90
1.2
1.2
—
—
—
0
0
12
72
1.70
0.86
22.3
10.8
—
—
—
0
0
13
80
1.66
0.86
1.1
1.2
—
—
—
0
0
9
149
0.59
0.81
1.1
1.4
—
—
—
0
0
237
2284
1.37
0.79
17.6
11.8
—
—
—
0
0
6
34
1.78
0.77
1.3
1.3
—
—
—
0
0
5
24
2.10
0.75
4.0
3.3
—
39.71
—
0
7
7
39
1.82
0.73
1.4
1.2
—
—
—
0
0
17
118
1.47
0.71
1.2
1.2
—
—
—
0
0
5
26
1.94
0.71
2.2
1.2
—
—
—
0
0
27
205
1.35
0.70
1.6
1.5
—
—
—
0
0
12
77
1.59
0.70
1.4
1.2
—
—
—
0
0
5
27
1.87
0.69
2.0
1.9
—
—
—
0
0
212
2024
1.24
0.68
4.6
4.2
5.79
5.89
mmol/l
0.73
200
1868
7
43
1.64
0.67
2.4
2.6
3.61
4.99
e9/l
—
7
43
7
44
1.61
0.65
2.7
3.1
57.71
58.73
%
—
7
44
21
155
1.39
0.65
1.6
1.4
—
—
—
0
0
32
253
1.30
0.65
1.1
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
0
22
0.00
0.59
0.0
1.9
—
—
—
0
0
200
2084
0.83
0.58
23.2
14.5
40.16
40.56
%
0.28
149
1613
26
203
1.31
0.58
1.1
1.2
—
—
—
0
0
66
576
1.19
0.57
3.5
4.0
5.47
8.58
mg/mmol
0.61
49
376
19
250
0.74
0.57
1.3
1.4
—
—
—
0
0
6
36
1.68
0.57
1.2
3.1
18.67
28.79
u/ml
—
6
36
6
37
1.64
0.56
1.0
1.2
—
—
—
0
0
250
2449
1.39
0.53
30.7
19.4
4.58
4.55
e12/l
0.47
245
2382
14
101
1.41
0.50
3.6
3.3
—
—
—
0
0
28
226
1.27
0.50
1.3
1.3
—
—
—
0
0
23
181
1.30
0.50
2.1
3.4
71.21
70.45
e9/l
0.03
16
134
7
110
0.63
0.49
1.6
1.7
—
—
—
0
0
35
297
1.21
0.42
1.7
2.6
52.10
128.69
ug/g
3.41
29
238
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
2.9
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
6.85
—
0
13
5
36
1.40
0.38
1.0
1.2
10.62
12.47
u/l
—
5
30
15
118
1.29
0.34
12.2
12.8
—
—
—
0
0
213
2086
1.11
0.24
5.0
4.3
4.68
4.70
mmol/l
0.11
205
1955
5
39
1.29
0.23
1.0
1.1
—
—
—
0
0
7
95
0.73
0.22
1.0
1.5
—
—
—
0
0
5
40
1.25
0.22
2.6
2.8
9.42
8.05
mmol/l
—
5
40
153
1481
1.08
0.22
5.1
3.4
61.82
48.20
u/l
0.61
145
1404
8
101
0.79
0.21
1.0
1.5
—
—
—
0
0
8
101
0.79
0.21
1.0
1.5
—
—
—
0
0
8
102
0.78
0.21
1.0
1.5
—
—
—
0
0
8
102
0.78
0.21
1.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
3.0
—
—
—
0
0
0
10
0.00
0.21
0.0
7.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
11.3
—
7.38
—
0
12
6
48
1.26
0.20
2.3
4.2
—
—
—
0
0
6
50
1.20
0.20
2.3
2.2
—
—
—
0
0
41
377
1.10
0.19
1.7
1.8
—
—
—
0
0
204
2003
1.08
0.18
4.6
3.8
1.39
1.30
mmol/l
0.76
195
1856
55
584
0.93
0.16
2.0
1.7
1.52
1.43
mmol/l
0.30
47
497
6
79
0.75
0.15
1.0
1.4
—
—
—
0
0
215
2120
1.08
0.14
5.4
4.7
2.83
2.81
mmol/l
0.12
206
1969
61
580
1.07
0.14
1.2
1.4
—
—
—
0
0
20
220
0.90
0.12
1.7
1.6
—
—
—
0
0
15
166
0.90
0.10
1.3
1.7
—
—
—
0
0
37
351
1.06
0.09
2.8
2.7
0.70
0.74
ug/l
0.09
23
216
6
54
1.11
0.09
1.2
1.2
—
—
—
0
0
6
57
1.05
0.08
1.3
1.3
—
—
—
0
0
19
177
1.08
0.07
3.7
3.1
—
—
—
0
0
25
257
0.97
0.01
1.3
1.6
—
—
—
0
0
208
2074
1.01
0.00
5.0
4.2
1.45
1.45
mmol/l
0.06
198
1929
10
105
0.95
0.00
1.2
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
2.7
—
2605.56
—
0
9
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
6
59
1.02
0.00
1.3
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
4.4
—
53.40
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
16.26
—
0
5
7
72
0.97
0.00
1.1
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
0.00
1.9
2.0
—
—
—
0
0
6
64
0.94
0.00
1.2
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
2.14
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint G6_MUSCOTHUNS and mortality.

Females

Parameter HR [95% CI] p-value
G6_MUSCOTHUNS 2.962 [2.19, 4.0] < 0.001
Birth year 0.992 [0.98, 1.0] 0.081

During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 719 females with G6_MUSCOTHUNS died.

Males

Parameter HR [95% CI] p-value
G6_MUSCOTHUNS 2.651 [2.11, 3.34] < 0.001
Birth year 0.987 [0.98, 1.0] 0.024

During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 773 males with G6_MUSCOTHUNS died.

Mortality risk

Mortality risk for people of age

years, who have G6_MUSCOTHUNS.

N-year risk Females Males
1 0.252% 0.384%
5 1.66% 2.69%
10 3.948% 6.826%
15 7.418% 13.381%
20 12.42% 22.845%

Relationships between endpoints

↥

Index endpoint: G6_MUSCOTHUNS – Other and unspecified primary disorders of muscles

GWS hits: 9

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data